Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PRLD
#2987
Prelude Therapeutics Incorporated
2.7
6
-5.80%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
-5.80%
Monthly Change
+28.37%
6 month change
+113.95%
Cambio anual
+253.85%
Cierres anteriores
2.9
3
Open
2.7
6
Bid
Ask
Low
2.7
6
High
2.7
6
Volumen
3
Markets
Acciones
Atención Sanitaria
PRLD
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
32.6 M
36.2 M
36.5 M
42.06 M
42.3 M
173.4 M
Valuation ratios
Enterprise value
3.11 B
561.19 M
209.92 M
198.24 M
57.85 M
124 M
Price to earnings ratio
—
—
-2.06
-2.01
-0.76
-2.7
Price to sales ratio
—
—
—
—
13.81
—
Price to cash flow ratio
—
—
-2.84
-2.29
-0.94
-3.15
Price to book ratio
—
—
1.22
1.04
0.74
1.26
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.25
0.37
0.52
0.44
0.72
0.87
Return on equity %
0.27
0.39
0.59
0.51
0.97
1.28
Return on invested capital %
10.89 K
8 576.16
4 233.67
2 161.61
1 600.72
—
Gross margin %
100
—
—
—
100
—
Operating margin %
534.21 K
—
—
—
1 995.91
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
517.54 K
—
—
—
1 816.76
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
19.41
15.37
9.42
10.79
5.3
17.36
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
—
0.03
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
1.77
1.77
1.36
1.32
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
7.87
7.3
1.76
4.75
Net current asset value per share
—
—
4.31
3.9
1.79
4.92
Tangible book value per share
—
—
4.13
3.93
1.73
4.86
Working capital per share
—
—
3.86
3.54
1.45
3.81
Book value per share
—
—
4.13
3.93
1.73
4.86
Noticias
Las acciones de Prelude Therapeutics reciben calificación reiterada de Mejor Rendimiento
Acciones de Prelude Therapeutics reciben calificación reiterada de Market Outperform
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens
Las acciones de Prelude Therapeutics suben tras aprobación de la FDA para fármaco contra el cáncer
Acciones de Prelude Therapeutics suben tras aprobación de la FDA para fármaco
Prelude Therapeutics stock surges after FDA clears IND for cancer drug
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Mizuho eleva calificación de Incyte a Outperform tras prometedores datos en ASH
Citizens reitera la calificación de Mejor Rendimiento para las acciones de Prelude Therapeutics
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
Incyte nombra a Richard Hoffman como vicepresidente ejecutivo y asesor jurídico
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus